RLMD: תחזית צמיחת רווחים לשנה הבאה Relmada Therapeutics

Relmada Therapeutics develops innovative antidepressants, offering rapid onset of action with low addiction risks. The projected change in earnings per share for the coming year allows for an assessment of market expectations, where the value -27.70 describes the current level. Relmada Therapeutics aims for expansion in neuropharmaceuticals by scaling REL-1017, completing final Phase III trials to launch sales in the US.

The investment potential assessment for Relmada Therapeutics (RLMD) is based on comparing the current share price with the expected earnings per share. The trend in consensus EPS forecasts for the coming year reflects the average expert growth rate for net income, allowing market noise to be filtered out from real trends. For Relmada Therapeutics (RLMD), this indicator confirms the monetization of antidepressants, where high patient loyalty guarantees a stable cash flow.